Skip to content
MARKETS / NASDAQ / NMAD
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Nomad Power Solutions, Inc. NMAD

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$-6.1M
In brief

What this company does

The Company’s drug product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company is focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity. LB-100 is currently being tested in clinical trials in Ovarian Clear Cell Carcinoma, Metastatic Micro Satellite Stable (MSS) Colon Cancer, and Advanced Soft Tissue Sarcoma. LB-100 has FDA Investigational New Drug status in the US and Investigational Medicinal Product Dossier approval in the European Union.

Written from the business description in Lixte Biotechnology Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth
Revenue, FY2025 · full 19-year series below
Revenue $M Net income $M
FY2015 · Revenue 0.2 · Net income -2.9
-2M2007201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
ROE
FY2025 · ROE -115.9%
-2000%-4000%2007201020132016201920222025

Each USD of equity lost 116 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Net buybacks $M Dividends $M
FY2018 · Dividends — · Net buybacks -4.5
-2M-4M2018

Total assetsUSD 12.7M
EquityUSD 9.7M
Current ratio3.88×

Equity funds 76% of total assets.

The 19-year record
19 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B··········0.0·0.00.00.00.0···
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0···
EBITDA $B············−0.0−0.0−0.0−0.0···
Income tax $B0.0··················
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−1.26−1.59−2.66−3.99−0.50−0.29−0.22−0.04−0.03−0.04−0.06−0.06−0.03−0.09−0.06−0.03···
Dividend / sh $···················
Payout %···················
ROE %−115.9−148.7−111.1−126.8−137.3−87.7−74.4−83.3−299.0−810.0−986.6−1101.8−159.1−455.7−227.8−58.0−317.4−4764.2−437.4
Shares out B0.010.000.000.000.010.010.010.070.060.050.050.050.040.040.040.04···

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 19 of 19 fiscal years. 28 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2007

Share this section

Download image